Australian Clinical Labs Ltd
ASX:ACL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Australian Clinical Labs Ltd
ASX:ACL
|
AU |
|
H
|
Healius Ltd
ASX:HLS
|
AU |
|
Integral Diagnostics Ltd
ASX:IDX
|
AU |
|
Rhythm Biosciences Ltd
ASX:RHY
|
AU |
|
Gujarat Fluorochemicals Ltd
NSE:FLUOROCHEM
|
IN |
|
Anupam Rasayan India Ltd
NSE:ANURAS
|
IN |
Wall Street
Price Targets
ACL Price Targets Summary
Australian Clinical Labs Ltd
According to Wall Street analysts, the average 1-year price target for
ACL
is 2.62 AUD
with a low forecast of 2.27 AUD and a high forecast of 4.04 AUD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ACL's stock price target?
Price Target
2.62
AUD
According to Wall Street analysts, the average 1-year price target for
ACL
is 2.62 AUD
with a low forecast of 2.27 AUD and a high forecast of 4.04 AUD.
What is Australian Clinical Labs Ltd's Revenue forecast?
Projected CAGR
3%
For the last 7 years the
compound annual growth rate for
Australian Clinical Labs Ltd's revenue is
10%.
The projected
CAGR
for the next 3 years is
3%.
What is Australian Clinical Labs Ltd's Operating Income forecast?
Projected CAGR
3%
The
compound annual growth rate
of Australian Clinical Labs Ltd's operating income for the next 3 years is
3%.
What is Australian Clinical Labs Ltd's Net Income forecast?
Projected CAGR
6%
The
compound annual growth rate
of Australian Clinical Labs Ltd's net income for the next 3 years is
6%.
